Poster Oral Presentation 2

[PO-013] Etrasimod for the treatment of ulcerative colitis: up to 4 years of safety data from the global clinical program

Dana Verbovsky, Séverine Vermeire¹, David T Rubin², Miguel D Regueiro³, *Ken Takeuchi⁴, Alissa Walsh⁵, Paulo G Kotze⁶, Aline Charabaty⁷, Martina Goetsch⁸, Krisztina Lazin⁸, Joseph Wu⁹, Georgios Tsamos¹⁰, Michelle Segovia¹¹, Diogo Branquinho¹¹, Silvio Danese¹² (1. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, 2. University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL, USA, 3. Department of Gastroenterology, Hepatology and Nutrition, Cleveland Clinic, Cleveland, OH, USA, 4. Department of Gastroenterology, IBD Centre, Tsujinaka Hospital Kashiwanoha, Kashiwa, Chiba, Japan, 5. Translational Gastroenterology Unit, Oxford University Hospital, Oxford, UK, 6. IBD Outpatient Clinics, Colorectal Surgery Unit, Pontifícia Universidade Católica do Paraná (PUCPR), Curitiba, Brazil, 7. Division of Gastroenterology and Hepatology, Johns Hopkins School of Medicine, Washington, DC, USA, 8. Pfizer AG, Zürich, Switzerland, 9. Pfizer Inc, Cambridge, MA, USA, 10. Pfizer, Thessaloniki, Central Macedonia, Greece, 11. Pfizer Inc, New York, NY, USA, 12. Division of Gastroenterology and Endoscopy, IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy)

Password required to view

Enter the password to view the abstracts.
The password will be emailed to those who have completed the registration.